At the news
? NEUTRALIMPACT 6/10 8-K filed Sep 1, 2026 at 07:10 ET
Invivyd appointed Chairman Marc Elia as CEO, replacing the CFO who had been serving as principal executive officer. The filing also announced top-line data from the VYD2311 Phase 3 DECLARATION and LIBERTY studies is expected around the end of Q3 2026, with the company planning to submit a BLA for either traditional or accelerated approval. This is a routine CEO appointment combined with a near-term binary catalyst from pivotal clinical readouts.
- Marc Elia appointed CEO effective August 30, 2026; he retains Chairman title.
- Elia receives $750,000 base salary, 70% target bonus, $500,000 sign-on bonus, and an option for 10,700,000 shares.
- Top-line data from VYD2311 DECLARATION and LIBERTY studies expected around end of Q3 2026.
- Company plans to submit a BLA for VYD2311 for either traditional or accelerated approval after data readout.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access